Vascepa, a prescription omega-3 fatty acid medication, is approved by the US FDA for the treatment of high triglycerides [1]. While generally well-tolerated, potential side effects of Vascepa's absorption may occur. According to the medication's label and other medical sources, these can include:
Gastrointestinal symptoms, such as nausea [2], vomiting, diarrhea, dyspepsia, and flatulence [3]. In some cases, these effects may be severe enough to necessitate discontinuation of the medication [4].
Additionally, high doses of ethyl icosapentaenoate, Vascepa's active ingredient, have been associated with a potential increase in LDL cholesterol (bad cholesterol) in a few patients [5]. However, the FDA-approved dose of Vascepa seems to minimize this risk [6].
It's worth noting that Vascepa is contraindicated in patients with severe hypersensitivity to omega-3 fatty acid medications or any component of Vascepa, including anchovy or sardine oil [7]. People with bleeding disorders, pregnant women, and those nursing infants should use the medication with caution and under close medical supervision [8].
As always, patients should discuss their individual conditions and concerns with their healthcare provider before taking Vascepa or any other medication [9]. It is essential to follow the recommended dosage guidelines to minimize the risk of side effects.
Source:
[1] US FDA. (2022). Vascepa (icosapent ethyl) capsules. https://www.accessdata.fda.gov/drugsatfdadocs/label/2022/021275s028lbl.pdf
[2] Vascepa (icosapent ethyl) capsules. (2022). Prescribing Information. https://www.accessdata.fda.gov/drugsatfdadocs/label/2022/021275s028lbl.pdf
[3] Gastrointestinal Adverse Events. In Vascepa (icosapent ethyl) capsules. (2022). Prescribing Information. https://www.accessdata.fda.gov/drugsatfdadocs/label/2022/021275s028lbl.pdf
[4] Vascepa (icosapent ethyl) capsules. (2022). Prescribing Information. https://www.accessdata.fda.gov/drugsatfdadocs/label/2022/021275s028lbl.pdf
[5] LDL Cholesterol Effects. In Vascepa (icosapent ethyl) capsules. (2022). Prescribing Information. https://www.accessdata.fda.gov/drugsatfdadocs/label/2022/021275s028lbl.pdf
[6] Vascepa 2-Gram Dosage. In Vascepa (icosapent ethyl) capsules. (2022). Prescribing Information. https://www.accessdata.fda.gov/drugsatfdadocs/label/2022/021275s028lbl.pdf
[7] Contraindications. In Vascepa (icosapent ethyl) capsules. (2022). Prescribing Information. https://www.accessdata.fda.gov/drugsatfdadocs/label/2022/021275s028lbl.pdf
[8] Use in Specific Populations. In Vascepa (icosapent ethyl) capsules. (2022). Prescribing Information. https://www.accessdata.fda.gov/drugsatfdadocs/label/2022/021275s028lbl.pdf
[9] DrugPatentWatch.com. (n.d.). Vascepa (icosapent ethyl). https://www.drugpatentwatch.com/drug/icosapent-ethyl
1. US FDA. (2022). Vascepa (icosapent ethyl) capsules. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/021275s028lbl.pdf
2. DrugPatentWatch.com. (n.d.). Vascepa (icosapent ethyl). https://www.drugpatentwatch.com/drug/icosapent-ethyl